Newsroom

August 30, 2024

Alnylam Logo
Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 30, 2024-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced detailed results from the HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM).

April 23, 2024

Read Now Button
2024 Spring Newsletter
Catch up on the latest happenings in our spring newsletter.
January 18, 2024

Newsletter logo
2024 Winter Newsletter

Explore the most recent updates in the 2024 Winter Newsletter.

December 27, 2023

AstraZeneca Logo
WAINUA (eplontersen) granted first-ever regulatory approval in the US for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis

December 21, 2023

US FDA approval based on NEURO-TTRansform Phase III results showing WAINUA demonstrated consistent and sustained benefit improving neuropathy impairment and quality of life

Additional regulatory reviews underway in rest of world